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INTRODUCTION
Flavonoids are polyphenol compounds containing
a unique C6-C3-C6 structure (diphenyl propane struc-
ture) and more than 4,000 varieties of flavonoids
are distributed in the plant kingdom. They are mostly
present as glycosides in which phenolic hydrogen
or hydrogens are substituted for the sugar moiety.
Flavonoids can be classified as calcones, flavones,
flavanones, flavanols and flavonols. Quercetin, a
typical flavonol, possesses additional phenolic OH
groups at the 5- and 7-position of the A ring and 3’-
and 4’-position of the B-ring (Fig.1). Quercetin
glycosides, such as rutin, quercitrin and quercimeritrin,
are common flavonoids present in fruits and vegeta-
bles. On the other hand, tea catechins consist of
four flavanol-type compounds containing additional
phenolic OH groups at the 5 and 7 position. Further-
more, (-)-epicatechin and (-)-epicatechin gallate
contain OH groups at the 3’and 4’position of the B
ring, and (-)-epigallocatehin and (-)-epigallocatechin,
at the 3’, 4’and 5’position, respectively. Interesting-
ly, epicatechin gallate and epigallocatechin gallate
are the derivatives of epicatechin and epigallocatechin
in which the gallate group is esterified to an OH
group at the 3-position of the flavanol structure.
Thus, tea catechins are composed of free flavanols
and their gallate esters.
Daily intake of flavonoids by humans is estimated
at 25 mg (1). However, this value only covers five
aglycones including quercetin and the total intake
of flavonoids from plant food may reach several
hundred mg/day (2). This level is not low as com-
pared with that of vitamin E or vitamin C. In 1936,
Szent-Györgyi (3) claimed that two flavonoids from
citrus fruits reduced capillary fragility and perme-
ability in humans and he named them vitamin P.
At present, flavonoids are not involved in the
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category of vitamins. Nevertheless, they are recog-
nized as having a potential beneficial effect in disease
prevention (4-9). Epidemiological studies strongly
suggest that consumption of fruits, vegetables and
teas lowers the risk of coronary heart disease (10).
It should be noted that an inverse relationship be-
tween the intake of flavonoids and coronary heart
disease risk was also reported (11, 12). The so-called
French paradox, the lack of a positive correlation
between a high intake of saturated fat and the
occurrence of coronary heart disease is related at
least partly to the consumption of red wine (13),
which is rich in flavonoids including epicatechin
and quercetin.
The antioxidant activity of flavonoids has been
frequently mentioned in connection with their
physiological function in vivo, because oxidative
stress is known to participate in the initial process
of atherosclerosis leading to coronary heart dis-
ease (6). A number of studies have revealed that
flavonoids act as antioxidants by scavenging reac-
tive oxygen species (ROS) and/or chelating metal
ion responsible for the generation of ROS. The
structure-activity relationship of flavonoids and their
antioxidant activity is well documented (14). We
have already carried out a kinetic study of the inhib-
itory effect of several flavonoids on lipid peroxidation
in solution and in liposomal membranes (15, 16).
The results implied that flavonoids act as interfacial
antioxidants in the lipid/water biphasic system,
because the hydrophilic property of the flavonoids
facilitates their localization at the interface of the
lipid bilayers resulting in an effective inhibition of
the initial attack by aqueous radicals (17). However,
the in vivo function of dietary flavonoids cannot be
estimated without a knowledge of their absorption
and metabolic fate. Thus, much study has been done
on the absorption and metabolism of flavonoids in
recent years. We are also investigating the absorption
rate and metabolic process of flavonoids, in particu-
lar, (-)-epicatechin and quercetin, in rat and human.
Here we review recent studies on the absorption
and metabolism of these two flavonoids.
ABSORPTION AND METABOLIC PATHWAY
OF DIETARY (-)-EPICATECHIN
In1971, Das et al. (18) detected (+)-catechin and
its metabolites in human urine after oral adminis-
tration of (+)-catechin. This was the first evidence
that catechins are absorbed into the human body.
It was recently confirmed that tea catechins are
absorbed into human body and accumulated in the
blood plasma by the intake of tea catechin concen-
trate (19, 20). A rat study (21) demonstrated that a
main component of tea catechin, (-)-epigallocatechin
gallate, was widely distributed in several tissues
Fig.1. Structures of (-)-epicatechin and quercetin
(-)-Epicatechin Quercetin
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including the liver and kidney. On the other hand,
Hackett (22) showed that oral administration of
epicatechin results in urinary excretion of glucuronide
and sulfate conjugates of epicatechin and 3’-O-methyl
epicatechin, indicating that absorbed catechins are
mostly subject to metabolic conversion into conju-
gates. It is also suggested that conjugated metabo-
lites come to bile from liver and are then reabsorbed
into the body after hydrolysis and ring-cleavage
(enterohepatic circulation) (23). It is therefore likely
that tea catechins accumulate in human plasma
through enterohepatic circulation.
In general, liver is a main tissue for the metabo-
lism of xenobiotic substances. However, intestinal
mucosa, kidney and other tissues also possess enzy-
matic activity for metabolism such as glucuronidation,
O-methylation, and hydroxylation (P-450). It is un-
clear how and where catechins are metabolized after
intestinal absorption. Here we used (-)-epicatechin
and measured the enzymatic activities for its meta-
bolic conversion in several rat tissues (24). The
enzymes are uridine-5’-diphosphoglucuronosyl
transferase (UGT) for glucuronidation, phenol-
sulfotransferase (PST) for sulfation and catechol-
O -methyltransferase (COMT) for methylation. Figure
2 shows that the UGT activity was strongest for the
preparation from the intestine. The only organ to
present activity of PST was the liver. The liver is the
main organ for COMT and the activity in the kidney
was lower than that in the liver but was higher than
in the other tissues. Thus, we propose a metabolic
pathway of orally administered (-)-epicatechin in rats
as shown in Fig. 3. Absorbed epicatechin is likely
to be immediately conjugated with glucuronic acid
in the intestinal mucosa. Conjugation in the intestinal
mucosa is plausible because the glucuronidation of
phenolic compounds in the intestinal mucosa has
been reported elsewhere (25). The second step for
metabolic conversion is conjugation with sulfate. The
final step is methylation resulting in O-methylated
catechin, which seems to be the final product of ab-
sorbed EC. We therefore postulate that epicatechin
is metabolized to glucuronyl conjugates in the
intestinal mucosa and these enter the portal vein
and are metabolized further in liver and other tis-
sues. Finally, they are excreted from the body via bile
or urine. The antioxidant activity of catechins has
been often discussed based on the results of in vitro
studies. However, the activity of their metabolites
should be taken into account when estimating their
in vivo effectiveness.
EX VIVO EFFECT OF (-)-EPICATECHIN
ON THE ANTIOXIDATIVE DEFENSE IN
RAT BLOOD PLASMA
Blood plasma is a well-organized defense system
which utilizing antioxidant enzymes such as extra-
cellular superoxide dismutase and glutathione per-
oxidase, and low-molecular weight antioxidants such
as vitamin E, vitamin C, uric acid and so on. It is of
interest to know the role of dietary catechins in
antioxidative defense in blood plasma, because
catechins are found to be mainly present as conju-
gated and methylated metabolites. It remains unclear
whether or not catechins possess any antioxidant
activity after intestinal absorption and metabolic
Fig.2. Tissue distribution of conjugative enzyme activities in
rats. Panels represent enzyme activities measured at tissue
preparation, of UGT (panel A), PST (Panel B), and COMT
(panel C). Activities were determined using (-)-epicatechin as
substrate. Values are the means±SEM. Means with different
letters are significantly different, P<0.05. (ref. 24)
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conversion. Thus, we measured the changes in the
oxidizability of rat plasma after oral administration
of (-)-epicatechin (26). Male Wistar rats were fasted
for 12-15 hr and then administered (-)-epicatechin
(10 or 50 mg/200 g body weight) dissolved in 2.0 ml
of water intragastrically by direct stomach intubation.
The rats were anesthetized with diethylether at 1 hr
and 6 hr after administration. Rat plasma was ob-
tained and the concentration of (-)-epicatechin and
its metabolites were determined by HPLC analysis
and a method of enzymatic hydrolysis which we
developed. Table 1 shows the profiles of metabolites
in rat plasma after (-)-epicatechin administration.
One hr after an intragastric administration of 20 mg
Table 1. Micromolar concentrations of (-)-epicatechin metabolites in rat plasma after intragastric administration of quercetin at two
dose levels.
Time after administration
conjugates 1 h 6 h
Dose 10 mg*
Free
Sulfate
Glucuronide
Sulfoglucuronide
Total
EC (µM)
3.0
1.0
25.2
0
29.2
Methyl-EC (µM)
0
1.3
7.4
4.4
13.1
EC (µM)
0
0
0.9
0
0.9
Methyl-EC (µM)
0
0.9
2.8
2.2
5.9
Dose 50 mg*
Free
Sulfate
Glucuronide
Sulfoglucuronide
Total
EC (µM)
13.3
0
52.1
0
65.4
Methyl-EC (µM)
0.9
7.6
5.9
23.2
37.6
EC (µM)
2.6
3.6
11.9
5.4
23.5
Methyl-EC (µM)
0.3
9.3
11.5
28.7
49.8
* Dose : mg of free quercetin/200 g of rat body weight.
EC : non methylated (-)-epicatechin.
Methyl-EC : methylated (-)-epicatechin (tentatively identified as (-)-epicatechin derivatives in which the hydroxyl group at the
3’-position was converted to a methoxyl group).
Fig.3. Proposed scheme of the metabolic fate of orally administered (-)-epicatechin in rats. COMT, catechol-O-methyltransferase ;
EC, (-)-epicatechin ; GlcA, glucuronide moiety ; Meth, methyl moiety ; PST, phenolsulfotransferase ; Sulf, sulfate moiety ; UGT,
uridine 5’-diphosphoglucuronosyltransferase (Ref. 24)
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(-)-epicatechin, the concentration of total (-)-epicatechin
metabolites that had accumulated was 42.3 µM. 70%
and 30% were nonmethylated and O-methylated
epicatechins, respectively. As little as 7% of the
metabolites were in a non-conjugated form. After 6
hr administration, approx. 84% of metabolites were
cleared from plasma. Administration of 50 mg
(-)-epicatechin increased the level of total metabo-
lites in plasma to 103.0 µM and 73.3 µM at 1 hr
and 6 hr, respectively. 13% free (-)-epicatechin was
detected in the plasma indicating saturation of the
conjugation reaction.
Fig.4 shows the accumulation of cholesteryl ester
hydroperoxides (CE-OOH) and consumption of
α-tocopherol in copper ion-induced oxidation of
diluted rat plasma. This figure clearly shows that
oral administration of (-)-epicatechin hindered the
accumulation of CE-OOH and retarded the con-
sumption of α-tocopherol. It is therefore likely that
oral administration of (-)-epicatechin expands the
antioxidative capacity of rat blood plasma, although
(-)-epicatechin is mostly present as its metabolites.
This implies that some (-)-epicatechin metabolites
act as antioxidants in plasma by scavenging radicals
and/or chelating metal ion.
Bors (27) suggested that theO-dihydroxyl structure
in the B-ring (catechol structure) is essential
to the free radical-scavenging activity for
flavanol-type flavonoids.Metabolites posses-
sing aO-dihydroxyl structure seem to be
responsible for the antioxidant activity
of orally administered (-)-epicatechin. A
human study (28)demonstrated that inges-
tion of tea improves the antioxidant ca-
pacity of blood plasma. It is therefore likely
that conjugatedmetaboliteswith a catechol
structure are responsible for the in vivo
antioxidant activity of tea catechins. Re-
cently Okusio et al. (29) and Harada et
al. (30) detected (-)-epicatechin-5-O-
glucuronide as a (-)-epicatechin metabo-
lite in rat blood plasma. This conjugated
metabolite contains a catechol structure
and thus may be responsible for the
antioxidant activity of dietary catechins.
ABSORPTION OF QUERCETIN AND
QUERCETIN GLYCOSIDES
In1975, Gugler et al. (31) reported that
less than 1% of quercetin wasabsorbed into
the human body following oral adminis-
tration of quercetin aglycone. Ueno (32)
et al. demonstrated usingC14-labeledquercetin
that 20% of quercetin was absorbed from
the digestive tract and present in bile and
urine as glucuronide and sulfate conjugates
within 48 hrs. We are interested in the
effects of the vehicles for quercetin in
oral administration on the efficiency of
intestinal absorption and accumulation
in blood(33). Quercetin’s solubility in the
vehicles used for its administration was
compared with respective absorption
Fig. 4. Accumulation of cholesteryl ester hydroperoxides (CE-OOH) and con-
sumption of α-tocopherol in CuSO4-induced oxidation of diluted rat plasma. (A)
Diluted plasma from 1hr after the administration of water and epicatechin. (B)
Diluted plasma from 6hr after the administration ofwater and epicatechin. Pooled
plasma from four rats of eachgroupwas diluted four timeswithPBS and incubated
with100µM CuSO4 at37℃for6hr. (○) control rat (▲) EC-administered rat
(10mg/200g b.wt), (■) EC-administered rat (50mg/200g b.wt). Solid line;
the amount of CE-OOH, Dotted line ; the amount of α-tocopherol (ref. 26).
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profiles. We compared water and propylene glycol as
vehicles for the administration in the rat. If quercetin’s
solubility in propylene glycol is taken as 1 (complete
solubilzaition), the relative solubility in water is1.6x
10-5. The results shown in Fig.5 clearly reveal that
the extent of quercetin absorption depends on the
solubility in the vehicle used for the administration.
It should be emphasized that the vehicles substantially
affect the efficiency of the absorption. Alcohol as a
vehicle may elevate the absorption of quercetin from
the digestive tract because of its high solubility.
Quercetin is, in general, present in the form of
glycosides in plant foods and thus the absorption of
quercetin glycosides need to be clarified to estimate
the physiological function of dietary quercetin.
Water-soluble glycosides seem to be little absorbed
because of their poor solubility in bile acid micelles
in the intestinal tract. However, in the large intestine,
glycosides are hydrolyzed to release aglycone by the
action of β-glycosidase in anaerobic enterobacteria
(34). Furthermore, a part of the aglycone is subjected
to ring scission (35). Thus, flavonoids improve their
lipophilicity resulting in high solubility in bile acid
micelles. Nevertheless, there have been contradic-
tory results on the intestinal absorption of quercetin
glycosides. Manach et al. (36) suggested that the
absorption of rutin (quercetin-3-rutinoside) in rats is
slower than that of the respective aglycone because
hydrolysis in the large intestine is required. On
the other hand, Holmann (37, 38) et al. claimed that
quercetin glucosides are absorbed more easily than
quercetin aglycone in humans. Papanga et al (39)
and Aziz et al. (40) reported that quercetin glucosides
are present in human plasma without metabolic
conversion. However, Manach et al. (41) suspected
that intact quercetin glucosides are present in blood
Fig.5. Quercetin metabolite concentrations in rat plasma after oral administration of 50 mg/kg quercetin in 2 ml of propylene glycol
(I) or water (II). Values are the mean±SEM (n=3) (ref.33).
J. Terao. Flavonoids as in vivo antioxidants１６４
circulation without metabolic conversion. They sug-
gested that conjugated metabolites including sulfates
and glucuronides exclusively accumulate in the
plasma after intake of quercetin glucosides from
plant food (42). It is still obscure whether or not
quercetin glucosides are absorbed directly or ab-
sorbed after hydrolysis in the tract. We pointed out
that β-glucosidase activity is present in rat intestinal
mucosa homogenate (43). Thus we suggest that
quercetin glucosides are hydrolyzed in the intestinal
mucosa and incorporated into the cell in which
glucuronidation occurs. The participation of the
glucose transporter in the cellular intake of quercetin
glucosides from diet has been reported (44, 45).
However, there is no direct evidence that this trans-
port system is responsible for the absorption of
quercetin glucosides (46). Our recent results suggest
that not glucosides but glucuronide conjugates ac-
cumulated in human plasma after intake of onion
rich in quercetin glucosides (unpublished data).
QUERCETIN METABOLITES ACT AS ANTI-
OXIDANTS ON LIPID PEROXIDAITON IN
RAT PLASMA
Absorbed quercetin seems to be metabolized
via the same pathway as (-)-epicatechin, in which
glucuronidation occurs at first (Fig 6). It was re-
ported that in a rat experiment isorhamnetin (3’-O-
methylated quercetin) and 4’-O-methylated quercetin
accumulated after oral administration of quercetin
(47). However, we found that glucuronide and sul-
fate conjugates without methylation also accumu-
lated in blood plasma after oral administration (33)
and thus supposed that some conjugates in circu-
lation act as antioxidants. For example, in metabolic
profiles of quercetin in the rat obtained after oral ad-
ministration of 2 mg and 5 mg of quercetin aglycone
in propylene glycol, respectively (Table 2) (48), at
1 hr and 6 hr after the administration neither free
quercetin nor free isorhamnetin was found in the
plasma, indicating that all of the absorbed quercetin
is present as conjugated metabolite in the circula-
tion. At 2.0 mg, 13 µM of quercetin accumulated at
Fig. 6. Proposed scheme of the metabolic pathway of orally ad-
ministered quercetin in rats.
Fig.7. Copper ion-induced lipid peroxidation of rat plasma ob-
tained 1 hr after the administration of propylene glycol (control ;
open symbols) or quercetin solution (closed symbols), 2 mg
(■) or 10 mg (▲)/200 g b. wt. Plasma from rats of each group
was pooled, diluted four times with PBS and incubated with
100 µMCuSO4 at 37℃ for up to 6 hr. (ref. 48).
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1 hr and 9 µM after 6 hr. When the dose was el-
evated to 10 mg, the concentration of quercetin was
89.4 and 35.3 µM, after 1 and 6 hr, respectively. The
antioxidant activity of quercetin-treated plasma was
determined after dilution by measuring the accu-
mulation of CE-OOH during the copper ion-induced
lipid peroxidation of rat plasma (Fig.7). Plasma
after administration of quercetin enhanced the
resistance against CE-OOH accumulation indicating
that quercetin metabolites participate in the anti-
oxidative defense in blood plasma. It can be con-
cluded that some conjugated metabolites of quercetin
inhibit copper ion-induced plasma oxidation. Thus,
quercetin possesses antioxidative activity for
copper-ion induced oxidation of plasma even after
its metabolic conversion. We are now trying to clari-
fy the metabolites responsible for the antioxidant
defense in blood.
CONCLUSION
(-)-Epicatechin and quercetin are obtained by the
daily intake of vegetables, fruits and tea. Intestinal
absorption and the subsequent metabolic conver-
sion should be taken into account when elucidating
their physiological functions. Although little is clear
as to their absorption and metabolism in humans,
studies indicate that both flavonoids are partly ab-
sorbed into the body and largely accumulated as
glucuronide and sulfate conjugates. Conjugated
metabolites containing a catechol group are likely
to be responsible for the increase of plasma anti-
oxidative capacity. Although the conjugation with
glucuronide and sulfate is a step in the detoxifica-
tion to lose the physicochemical activity, intermedi-
ate products should retain their activity. Metabolites
may be at least partly responsible for the physiologi-
cal function of dietary flavonoids.
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